Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the United States Designated/Elected Office(DO/EO/US) Concerning a Submission Under 35 U.S.C. 371"
Approved for use through 3/31/2007. OMB 0651-0021

U. S. PAT	ATTORNEY'S DOCKET NUMBER								
U.S.	21540P								
TRANSMITTAL LETTER DESIGNATED/ELECTE CONCERNING A FILIN	U.S. APPLICATION NO. (If known see 37 CFR 1.5)								
INTERNATIONAL APPLICATION NO.		PRIORITY DATE CLAIMED							
PCT/US2005/002454	26 January 2005	28 Janaury 2004							
TITLE OF INVENTION									
AMINOCYCLOPENTYL PYRIDOPYRAZINONE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY									
APPLICANT(S) FOR DO/EO/US GABOR BUTORA, DEODIALSINGH GUIADEEN, SHANKARAN KOTHANDARAMAN, MALCOLM MACCOSS, SANDER G. MILLS AND LIHU YANG									
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:									
1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.									
2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.									
3. This is an express request to begin national examination procedures [35 U.S.C. 371(f)]. The submission must include items (5), (6), (9) and (21) indicated below.									
4. X The US has been elected (PG	CT Article 31).								
5. X A copy of the International A	Application as filed [35 U.S.C. 371(c)(	2)]							
a. is attached hereto (required only if not communicated by the International Bureau).									
b. has been communicated by the International Bureau.									
c. X is not required, as the	c. X is not required, as the application was filed in the United States Receiving Office (RO/US).								
6. An English language translation of the International Application as filed [35 U.S.C. 371(c)(2)].  a. is attached hereto									
b. has been previously submitted under 35 U.S.C. 154(d)(4).									
7. Amendments to the claims of the International Application under PCT Article 19 [35 U.S.C. 371(c)(3)].  a. are attached hereto (required only if not communicated by the International Bureau).									
b. have been communicated by the International Bureau.									
c. have not been made; however, the time limit for making such amendments has NOT expired.									
d. have not been made a	d. have not been made and will not be made.								
3. An English language translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 371(c)(3)].									
9. An oath or declaration of the	2. An oath or declaration of the inventor(s) [35 U.S.C. 371(c)(4)].								
10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 [35 U.S.C. 371(c)(5)].									
Items 11 to 20 below concern other document(s) or information included:									
11. X An Information Disclosure Statement under 37 CFR 1.97 and 1.98.									
An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.									
13. A preliminary amendment.									
14. An Application Data Sheet under 37 CFR 1.76.									
15. A substitute specification.									
16. A power of attorney and/or change of address letter.									
17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.									
18. A second copy of the published International Application under 35 U.S.C.154(d)(4).									
19. A second copy of the English language translation of the international application under 35 U.S.C.154(d)(4).									
20. Other items or information:									

Substitute for PTO-1390 (Rev. 07-2005) "Transmittal Letter to the med Series Designated/Elected Office(DO/EO/US)Concerning a Submission Under 35 U.S.C. 371"

Annoved for use through 3/31/2007. OMB 0651-0021

U.S. APPLICATION N	). (If known se	e 17 CFR	1-5)	INTERN	ATIONAL APPLICATION NO.			ATTORNEY'S DOC	KET NUMBER
U.S. APPLICATION NO. (If LINOVIL See 17 CFR 5)  PCT/US2005/002454				21540P					
The following fees are submitted:						CALCULATIONS	PTO USE ONLY		
21. Sasic national fee				\$300	\$300.00				
22. Examination fee (37 CFR 1.492(c))									
					preliminary examination repor PCT Article 33(1)-(4)		so		
All other situations								\$0.00	
23. Search fee (37 CFR 1.492(b))									
					inary examination report preparation report report preparation report				
Search fee [37 CFR 1.	445(a)(2)] ha	s been pa	aid on the	internatio	onal application to the USPTO	as aı	n	£100.00	
International Searching Authority						\$100	\$100.00		
					••••••				
All other situations				•••••	TOTAL OF 2			\$400.00	
Additional fee fo	or specificatio	n and dr	awings fil	led in pap	er over 100 sheets (excluding			\$400.00	
	m listing filed				The fee is \$250 for each addi				
Total Sheets	Extra Sheet	ts			dditional 50 or fraction to a whole number)	·	RATE		
107 - 100 =	7	/50	0.14	=	1	x	\$250.00	\$250.00	
_		ng the oa	th or decl	aration la	ter than 30 months from the ea	arliest	claimed		
priority date [37 CFI		JMBER	FILED		NUMBER EXTRA		RATE		
Total Claims			27	- 20 =	7	x	\$50.00	\$350.00	
Independent Claims			1	- 3 =	.0	x	\$200.00	\$0.00	
						\$360.00			
						=	\$1,000.00		
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)].									
TOTAL NATIONAL FEE =						=	\$1,000.00		
Fee for recording the enclosed assignment [37 CFR 1.21(h)]. The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31).\$40.00 per property.									
TOTAL FEES ENCLOSED =						=	\$1,000.00		
							Amount to be		
					refunded:	<u>.</u>			
·					Amount to be				
charged:									
a. A check in the amount of \$ to cover the above fees is enclosed.  b. Please charge my Deposit Account No. 13-2755 in the amount of \$1,000.00 to cover the above fees.									
A duplicate copy of this sheet is enclosed.									
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to the Deposit Account No. 13-2755. A duplicate copy of this sheet is enclosed.									
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive [37 CFR 1.137(a) or (b)] must be filed and granted to restore the International Application to pending status.									
SEND ALL CORRESPONDENCE TO:									
Customer No. 000210									
MERCK & CO., INC.									
Patent Department, RY60-30									
P.O. Box 2000 SIGNATURE									
126 East Lincoln Avenue Rahway, New Jersey 07065-0970									
David A. Rubin NAME									
DATE: July 21, 2006									
PHONE #: (7.	PHONE #: (732) 594-2675 40,314 REGISTRATION 1						TRATION N	UMBER	

## Page 1A of TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

Attorney Docket No.:	21540P		
International Appln No.:	PCT/US2005/002454		
International Filing Date:	26 January 2005		
Priority Date:	28 January 2004		

Title: AMINOCYCLOPENTYL PYRIDOPYRAZINONE

MODULTORS OF CHEMOKINE RECEPTOR ACTIVITY

Inventors: GABOR BUTORA

**DEODIALSINGH GUIADEEN** 

SHANKARAN KOTHANDARAMAN

MALCOLM MACCOSS SANDER G. MILLS

LIHU YANG

**EXPRESS MAIL CERTIFICATE** 

DATE OF DEPOSIT 21 July 2006

EXPRESS MAIL NO. EV 835851795 US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450.

MAILED BY Kathy Klithowski DATE 121-06